Kelsey Alvarez, RN

Memorial Sloan Kettering Cancer Center
Leukemia Service, Department of Medicine
1275 York Avenue
New York, NY
USA 10065
233 Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
354 Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study